Page 1

Amyris Investor Relations Amyris , Inc. Reports Second Quarter 2021 Financial Results Another record quarter of underlying revenue Another record quarter of consumer revenue and significant gross margin expansion -- Strong cash position and robust outlook into second half 2021 EMERYVILLE , Calif . , Aug. 5 , 2021 / PRNewswire / -- Amyris , Inc. ( Nasdaq : AMRS ) , a leading synthetic biotechnology company active in the Clean Health , Beauty and Wellness markets through its consumer brands and a top supplier of sustainable and natural ingredients , today announced financial results for its second quarter ended June 30 , 2021 . " With Q2 we completed another quarter of strong strategic and operational execution , " said John Melo , President and Chief Executive Officer . " We delivered record underlying revenue driven by record consumer revenue while significantly improving margins year - over - year . Two of our homegrown clean beauty brands , Biossance and Pipette , delivered record revenue with Biossance doubling revenue versus the prior year quarter . The performance of these brands is evidence of the rapidly growing consumer demand for high performance , affordable , and sustainable clean beauty products . In addition to our reported revenue , we had sales of $ 2.4 million that did not make the quarter cutoff . During Q2 , we made significant efforts and investments in marketing and supply chain for the Q3 launch of our new brands : Rose Inc. , JVN , Terasana and Olika which will add significant new revenue to our consumer portfolio in the second half . " " We are making good progress with the construction of our new Brazil ingredients manufacturing plant and expect to complete construction by the end of this year , " Mr. Melo added . " Early in the quarter , we completed a strategic transaction with Ingredion for the exclusive licensing of our Reb M sweetener from fermentation . We are aggressively working towards human trials to support worldwide accessibility to our RNA COVID - 19 vaccine . Pre - clinical results have demonstrated a strong potential to become a highly competitive booster and RNA delivery technology . " " 2021 is on track to be another record year with expected total revenue north of $ 400 million and positive adjusted EBITDA . As leaders in the creation of sustainable ingredients and products through clean chemistry and a strong product commercialization track record , we set ambitious operational and financial goals and are planning to reach $ 2 billion revenue in 2025. With our expanding ingredients pipeline and partnerships , strong manufacturing demand , and rapid consumer sales growth , we have confidence that we can achieve our objectives , while constantly finding ways to challenge the status quo and effect positive change for people and the planet , " concluded Mr. Melo . Q2 2021 Financial Highlights • Total revenue of $ 52.3 million included record underlying and consumer revenue and included $ 10 million of proceeds resulting from the strategic Reb M sweetener transaction . Total underlying revenue ( product and collaboration revenue ) increased 41 % to $ 42.3 million compared to Q2 2020 revenue driven by a 59 % increase in consumer sales , and a 25 % increase in ingredient sales . Q2 consumer revenue achieved a new record with Biossance doubling its revenue compared to the prior year quarter . • Non - GAAP gross margin of $ 27 million , or 51 % of revenue , improved from $ 11 million or 36 % of revenue in Q2 2020. Excluding the $ 10 million contribution from the strategic Reb M sweetener transaction , gross margin of $ 17 million represented a $ 6 million improvement compared to Q2 2020 due to consumer - related margin growth . • Cash operating expense of $ 63 million increased by $ 20 million , or 46 % compared to Q2 2020 primarily due to a $ 13 million increase in selling expense , of which $ 5 million related to pre - launch investments in new consumer brands , and $ 5 million to additional R & D spend . Prior year benefited from reduced business activity due to COVID .